Bio-Techne Corporation (TECH)

US — Healthcare Sector
Peers: UTHR  INCY  PCVX  LEGN  ASND  CRL  BIO  TFX  STE 

Automate Your Wheel Strategy on TECH

With Tiblio's Option Bot, you can configure your own wheel strategy including TECH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol TECH
  • Rev/Share 7.681
  • Book/Share 12.1928
  • PB 4.3329
  • Debt/Equity 0.2314
  • CurrentRatio 3.4592
  • ROIC 0.058

 

  • MktCap 8282000610.0
  • FreeCF/Share 1.4028
  • PFCF 37.5167
  • PE 63.1443
  • Debt/Assets 0.1736
  • DivYield 0.0061
  • ROE 0.0646

 

  • Rating
  • Score
  • Recommendation
  • P/E Score
  • DCF Score
  • P/B Score
  • D/E Score

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Resumed TECH Stephens -- Overweight -- $65 July 22, 2025
Initiation TECH TD Cowen -- Buy -- $65 July 9, 2025
Initiation TECH Wells Fargo -- Overweight -- $59 May 30, 2025
Downgrade TECH KeyBanc Capital Markets Overweight Sector Weight -- -- April 9, 2025
Initiation TECH Evercore ISI -- Outperform -- $75 March 18, 2025
Downgrade TECH Robert W. Baird Outperform Neutral $88 $68 Feb. 19, 2025

News

Bio-Techne Stock Set to Benefit From Expansion of RNAscope Menu
TECH
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive

TECH unveils the RNAscope Probes menu for human and mouse transcriptome to advance spatial biology.

Read More
image for news Bio-Techne Stock Set to Benefit From Expansion of RNAscope Menu
Bio-Techne Launches Expanded Menu of RNAscope Probes for Human and Mouse Transcriptome to Advance Spatial Biology
TECH
Published: February 20, 2025 by: PRNewsWire
Sentiment: Neutral

MINNEAPOLIS , Feb. 20, 2025 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global leader in life science tools and reagents, today announced the launch of an expanded menu of human and mouse RNAscope™ in situ hybridization probes to advance spatial biology research and the development of next-generation therapeutics and diagnostics. Designed to deliver spatial precision with industry-leading sensitivity and specificity, the Advanced Cell Diagnostics (ACD) branded RNAscope probe portfolio now includes over 70,000 unique probes across over 450 species.

Read More
image for news Bio-Techne Launches Expanded Menu of RNAscope Probes for Human and Mouse Transcriptome to Advance Spatial Biology
Bio-Techne Announces Release of GMP TcBuster Non-Viral Genome Engineering System
TECH
Published: February 18, 2025 by: PRNewsWire
Sentiment: Neutral

MINNEAPOLIS , Feb. 18, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative life science research tools, is pleased to announce the official release of GMP Transposase mRNA for the TcBuster™ non-viral genome engineering system, supporting the development and manufacture of immune cell- and stem cell-based therapies. The TcBuster System has been widely used by researchers to introduce large cargo genetic modifications in a range of cell types.

Read More
image for news Bio-Techne Announces Release of GMP TcBuster Non-Viral Genome Engineering System

About Bio-Techne Corporation (TECH)

  • IPO Date 1989-02-09
  • Website https://www.bio-techne.com
  • Industry Biotechnology
  • CEO Kim Kelderman
  • Employees 3100
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.